A detailed history of Glen Eagle Advisors, LLC transactions in Repligen Corp stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 10,471 shares of RGEN stock, worth $1.6 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
10,471
Previous 20,943 50.0%
Holding current value
$1.6 Million
Previous $2.6 Billion 46.27%
% of portfolio
0.19%
Previous 0.4%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$111.43 - $134.0 $1.17 Million - $1.4 Million
-10,472 Reduced 50.0%
10,471 $1.4 Billion
Q2 2025

Aug 14, 2025

BUY
$108.89 - $145.23 $2.28 Million - $3.04 Million
20,943 New
20,943 $2.6 Billion

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $8.46B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Glen Eagle Advisors, LLC Portfolio

Follow Glen Eagle Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Glen Eagle Advisors, LLC with notifications on news.